These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 32482034)
1. [Acute myocarditis caused by anti-PD-1 monoclonal antibody in the treatment of refractory Hodgkin lymphoma: a case report]. Shi XL; Wang D; Xu B; Xiao Y Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):424-425. PubMed ID: 32482034 [No Abstract] [Full Text] [Related]
2. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab in classical Hodgkin's lymphoma. Maly J; Alinari L Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112 [TBL] [Abstract][Full Text] [Related]
4. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442 [TBL] [Abstract][Full Text] [Related]
5. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. Villasboas JC; Ansell SM Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822 [TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin for the treatment of CD30+ lymphomas. Foyil KV; Bartlett NL Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188 [TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin. Deng C; Pan B; O'Connor OA Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186 [TBL] [Abstract][Full Text] [Related]
11. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review. Dada R Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203 [TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. Villasboas JC; Ansell S Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012 [TBL] [Abstract][Full Text] [Related]
14. [Application of anti-programmed cell death protein 1 antibody in children with refractory or relapsed Hodgkin lymphoma]. Li Y; Duan YL; Huang M; Zhang L; Jin YG; Zhang XL; Wang X Zhonghua Er Ke Za Zhi; 2022 Jun; 60(6):573-577. PubMed ID: 35658365 [No Abstract] [Full Text] [Related]
15. [Not Available]. Bounaix L; Bendouda M; Bay JO; Lemal R Bull Cancer; 2016 Nov; 103 Suppl 1():S160-S163. PubMed ID: 28057180 [TBL] [Abstract][Full Text] [Related]
16. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390 [TBL] [Abstract][Full Text] [Related]
17. Haematological cancer: PD-1 blockade: opening the door to attack. Hutchinson L Nat Rev Clin Oncol; 2015 Feb; 12(2):65. PubMed ID: 25533946 [No Abstract] [Full Text] [Related]
18. Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD. Klobuch S; Weber D; Holler B; Herr W; Holler E; Wolff D Oncol Res Treat; 2017; 40(7-8):447-450. PubMed ID: 28683452 [TBL] [Abstract][Full Text] [Related]
19. Tislelizumab: First Approval. Lee A; Keam SJ Drugs; 2020 Apr; 80(6):617-624. PubMed ID: 32185681 [TBL] [Abstract][Full Text] [Related]